D.A. Davidson & Co. Corbus Pharmaceuticals Holdings, Inc. Transaction History

D.A. Davidson & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$1.27 - $3.42 $27,580 - $74,272	-21,717 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$0.94 - $1.89 $21,814 - $43,861	-23,207 Reduced 51.66%	21,717 $27,000
Q3 2020 Nov 02, 2020	SELL	$1.5 - $9.38 $18,564 - $116,086	-12,376 Reduced 21.6%	44,924 $81,000
Q2 2020 Aug 10, 2020	BUY	$4.79 - $8.39 $15,328 - $26,848	3,200 Added 5.91%	57,300 $481,000
Q1 2020 May 05, 2020	SELL	$3.44 - $7.21 $3,440 - $7,210	-1,000 Reduced 1.81%	54,100 $283,000

Q4 2019 Feb 14, 2020	BUY	$4.29 - $5.64 $2,145 - $2,820	500 Added 0.92%	55,100 $301,000
Q3 2019 Nov 05, 2019	BUY	$4.87 - $7.08 $19,801 - $28,787	4,066 Added 8.05%	54,600 $266,000
Q1 2019 May 13, 2019	BUY	$5.76 - $8.95 $81,066 - $125,962	14,074 Added 38.6%	50,534 $351,000
Q4 2018 Jan 29, 2019	BUY	$5.26 - $7.97 $83,108 - $125,926	15,800 Added 76.48%	36,460 $213,000
Q3 2018 Nov 13, 2018	BUY	$4.65 - $7.95 $96,069 - $164,247	20,660 New	20,660 $156,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $6.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.